Role of 18F-FDG PET/CT in Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

Role of 18F-FDG PET/CT in Gastric Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05687552
• Other study ID #: gastric cancer
• Status: Not yet recruiting
• Start date: January 2023
• Est. completion date: January 2024

Study information

• Verified date: January 2023
• Source: Sohag University
• Contact: sara saber, ass lec
• Phone: 01097661576
• Email: jasmenahmed90[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of the study is to assess the value of PET/CT in diagnosis, staging, response evaluation, and relapse monitoring of gastric cancer.

Description:

gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer mortality worldwide (1) It carries a poor prognosis, with a 5-year survival of only 20%-30% (2) Clinical staging, based mainly on imaging, is critical in determining the best treatment.There is a widely accepted consensus of the usefulness of FDG PET/CT in staging and restaging of gastric cancer. According to evidence-based data, this modality can evaluate gastric cancer more accurately and is helpful for evaluation of tumor biologic characteristics, detection of lymph node and distant metastases, assessment of tumor response to therapy(9).

retrospective and prospective study will conducted at Sohag oncology hospital, nuclear medicine unit& Assuit university hospital, nuclear medicine unit including 50 patients in 12 months .

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: January 2024
• Est. primary completion date: December 2023
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. patients diagnosed as GC on surgically resected specimens;

2. Patients with gastric and extragastric metastasis.

3. patients with gastric cancer either operated or not.

Exclusion Criteria:

1. Patients with second malignancy.

2. Patient without proven pathology of cancer stomach.

3. Severely ill patient (patient with disturbed conscious level, or couldn't lay supine during the imaging).

4. uncontrolled diabetic patient with blood glucose level more than 200mg\dl.

5. pregnant women

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Device:
• pet -ct
assessment of added value of pet -ct in patients with gastric cancer and how patient get benefit from this finding

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sohag University

References & Publications (3)

Liu Q, Li J, Xin B, Sun Y, Feng D, Fulham MJ, Wang X, Song S. 18F-FDG PET/CT Radiomics for Preoperative Prediction of Lymph Node Metastases and Nodal Staging in Gastric Cancer. Front Oncol. 2021 Sep 13;11:723345. doi: 10.3389/fonc.2021.723345. eCollection — View Citation

Saka M, Katai H, Fukagawa T, Nijjar R, Sano T. Recurrence in early gastric cancer with lymph node metastasis. Gastric Cancer. 2008;11(4):214-8. doi: 10.1007/s10120-008-0485-4. Epub 2009 Jan 8. — View Citation

Tang L, Wang XJ, Baba H, Giganti F. Gastric cancer and image-derived quantitative parameters: Part 2-a critical review of DCE-MRI and 18F-FDG PET/CT findings. Eur Radiol. 2020 Jan;30(1):247-260. doi: 10.1007/s00330-019-06370-x. Epub 2019 Aug 7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	comparison of pet -ct finding with ct finding	The 18F-FDG PET/CT scan is visually estimated in the patients included in the study and quantitatively assessed by estimation of standardized uptake value(suv max). Statistical analysis of the included quantitative data.	base line